Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 5/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | ACE | P12821 | 1/20 | 0.47 |
| ▸ | GNPAT | O15228 | 1/20 | 0.46 |
| ▸ | ECE1 | P42892 | 2/20 | 0.46 |
| ▸ | ENPEP | Q07075 | 5/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8380946 | 1.00 | MME (0.51) | MMECA2CA4ACEGNPAT | |
| SCHEMBL23408821 | 0.85 | MME (0.42) | MMECA2CA4ACEGNPAT | |
| SCHEMBL10053584 | 0.85 | MME (0.50) | MMECA2CA4ACEGNPAT | |
| SCHEMBL26917989 | 0.85 | ACE (0.50) | MMEACEECE1ENPEP | |
| SCHEMBL17323631 | 0.85 | ACE (0.46) | MMEACEGNPATECE1 | |
| SCHEMBL30355295 | 0.83 | MME (0.49) | MMECA2CA4ACEGNPAT | |
| SCHEMBL24994842 | 0.83 | ECE1 (0.65) | MMECA2ACEECE1 | |
| SCHEMBL29378709 | 0.83 | MME (0.49) | MMECA2CA4ACEGNPAT | |
| SCHEMBL23380919 | 0.83 | ECE1 (0.46) | MMEACEGNPATECE1ENPEP | |
| SCHEMBL7825934 | 0.83 | MME (0.49) | MMECA2CA4ACEGNPAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250025438-A1 | Derivative of aspartic acid and use thereof in treatment of metabolic diseases such as hepatic fibrosis and non-alcoholic hepatitis | SHENZHEN JINGTAI TECHNOLOGY CO., LTD. (CN) | 2025-01-23 | — | — | US | disclosed |
| CN-118234705-A | Aspartic acid derivative and application thereof in treatment of liver fibrosis, nonalcoholic hepatitis and other metabolic diseases | 深圳利沃生物医药科技有限公司 | 2024-06-21 | — | — | CN | disclosed |
| WO-2023083291-A1 | DERIVATIVE OF ASPARTIC ACID AND USE THEREOF IN TREATMENT OF METABOLIC DISEASES SUCH AS HEPATIC FIBROSIS AND NON-ALCOHOLIC HEPATITIS | 深圳利沃生物医药科技有限公司 | 2023-05-19 | — | — | WO | disclosed |
| WO-2023083291-A1 | DERIVATIVE OF ASPARTIC ACID AND USE THEREOF IN TREATMENT OF METABOLIC DISEASES SUCH AS HEPATIC FIBROSIS AND NON-ALCOHOLIC HEPATITIS | 深圳利沃生物医药科技有限公司 | 2023-05-19 | — | — | WO | disclosed |
| US-7977339-B2 | Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2011-07-12 | — | — | US | disclosed |
| US-20100311649-A1 | SUBSTITUTED IMIDAZOLE 4-CARBOXAMIDES AS CHOLECYSTOKININ-1 RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2010-12-09 | — | — | US | disclosed |
| US-7795265-B2 | Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20090118300-A1 | Substituted Imidazole 4-Carboxamides as Cholecystokinin-1 Receptor Modulators | MERCK SHARP & DOHME LLC | 2009-05-07 | — | — | US | disclosed |
| US-5952503-A | Method for producing optically-active 2-piperazinecarboxylic acid derivatives | TORAY INDUSTRIES, INC. (JP) | 1999-09-14 | — | — | US | disclosed |
| EP-0906906-A1 | PROCESS FOR PREPARING OPTICALLY ACTIVE 2-PIPERAZINECARBOXYLIC ACID DERIVATIVES | TORAY INDUSTRIES, INC. (JP) | 1999-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118300-A1 | Substituted Imidazole 4-Carboxamides as Cholecystokinin-1 Receptor Modulators | CCKAR, CCKBR, GPR119 | MME 3110/4885CA2 1326/4885CA4 1513/4885 |
| US-20100311649-A1 | SUBSTITUTED IMIDAZOLE 4-CARBOXAMIDES AS CHOLECYSTOKININ-1 RECEPTOR MODULATORS | CCKAR, CCKBR, GPR119 | MME 3110/4885CA2 1326/4885CA4 1513/4885 |
| US-20250025438-A1 | Derivative of aspartic acid and use thereof in treatment of metabolic diseases such as hepatic fibrosis and non-alcoholic hepatitis | GOT1, GOT2, GLS2 | MME 663/4885CA2 2121/4885CA4 1466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.